BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ponce-de-León S, Torres M, Soto-Ramírez LE, José Calva J, Santillán-Doherty P, Carranza-Salazar DE, Carreño JM, Carranza C, Juárez E, Carreto-Binaghi LE, Ramírez-Martínez L, la Rosa GP, Vigueras-Moreno R, Ortiz-Stern A, López-Vidal Y, Macías AE, Torres-Flores J, Rojas-Martínez O, Suárez-Martínez A, Peralta-Sánchez G, Kawabata H, González-Domínguez I, Martínez-Guevara JL, Sun W, Sarfati-Mizrahi D, Soto-Priante E, Chagoya-Cortés HE, López-Macías C, Castro-Peralta F, Palese P, García-Sastre A, Krammer F, Lozano-Dubernard B. Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico. medRxiv 2022:2022. [PMID: 35169806 DOI: 10.1101/2022.02.08.22270676] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Chia TRT, Young BE, Chia PY. The Omicron-transformer: Rise of the subvariants in the age of vaccines. Ann Acad Med Singap 2022;51:712-729. [DOI: 10.47102/annals-acadmedsg.2022294] [Reference Citation Analysis]
2 Lee J, Khang D. Mucosal delivery of nanovaccine strategy against COVID-19 and its variants. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.11.022] [Reference Citation Analysis]
3 García-Sastre A. Mucosal delivery of RNA vaccines by Newcastle disease virus vectors. Curr Res Immunol 2022;3:234-8. [PMID: 36245642 DOI: 10.1016/j.crimmu.2022.10.001] [Reference Citation Analysis]
4 Madhavan M, Ritchie AJ, Aboagye J, Jenkin D, Provstgaad-Morys S, Tarbet I, Woods D, Davies S, Baker M, Platt A, Flaxman A, Smith H, Belij-Rammerstorfer S, Wilkins D, Kelly EJ, Villafana T, Green JA, Poulton I, Lambe T, Hill AVS, Ewer KJ, Douglas AD. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial. EBioMedicine 2022;:104298. [PMID: 36229342 DOI: 10.1016/j.ebiom.2022.104298] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 González-Domínguez I, Martínez JL, Slamanig S, Lemus N, Liu Y, Lai TY, Carreño JM, Singh G, Singh G, Schotsaert M, Mena I, McCroskery S, Coughlan L, Krammer F, García-Sastre A, Palese P, Sun W. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. Microbiol Spectr 2022;:e0153822. [PMID: 35658571 DOI: 10.1128/spectrum.01538-22] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Fulber JPC, Kamen AA. Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use. Viruses 2022;14:975. [DOI: 10.3390/v14050975] [Reference Citation Analysis]
7 González-domínguez I, Martínez JL, Slamanig S, Lemus N, Liu Y, Lai TY, Carreño JM, Singh G, Singh G, Schotsaert M, Mena I, Mccroskery S, Coughlan L, Krammer F, García-sastre A, Palese P, Sun W. Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice.. [DOI: 10.1101/2022.03.21.485247] [Reference Citation Analysis]
8 O’donnell KL, Gourdine T, Fletcher P, Shifflett K, Furuyama W, Clancy CS, Marzi A. VSV-Based Vaccines Reduce Virus Shedding and Viral Load in Hamsters Infected with SARS-CoV-2 Variants of Concern. Vaccines 2022;10:435. [DOI: 10.3390/vaccines10030435] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]